P132 Intermediate follow up of radiological interstitial changes for COVID-19 patients over the first year post discharge: a longitudinal study

P132 Table 1Follow up symptoms and radiological findings at first and second assessment post discharge. Analysed by Wilcoxon Rank Sum, median (range) First timepoint Second timepoint P value Clinic assessment (months post discharge) 1.5 (1–3) 9 (6–12) CT scan (months post discharge) 2.5 (1–4) 8 (6–12) MRC score 3 (2–4) 1 (1–3) <0.0001 CAT score 12 (7–18) 6 (4–14) 0.002 Numbers of CT performed 81 35 Numbers of CTs performed for isolated ground glass abnormalities (PCVCT1+2) 47 13 Numbers of CTs performed for fibrosis plus ground glass changes (PCVCT3) 34 22 ConclusionThose patients found to have PCVCT3 changes on initial CT should receive long term follow up as a proportion (approximately 9%) of them may develop progressive fibrotic changes. However this is likely to only represent less than 1% of all COVID-19 patients discharged from hospital. Longer term follow up is needed to determine the ongoing trajectory of these interstitial changes. These patients may potentially benefit from clinical trials in the future for the use of antifibrotics.ReferencesHuang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32.BSTI. BSTI Post-COVID-19 CT Report Codes. BSTI 22-May-2020.